SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

NCT02334865 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Partial Response of Multiple Myeloma or Plasma Cell Leukemia
Plasma Cell Myeloma

Interventions

BIOLOGICAL: Incomplete Freund's Adjuvant
OTHER: Laboratory Biomarker Analysis
DRUG: Lenalidomide
BIOLOGICAL: Sargramostim
BIOLOGICAL: SVN53-67/M57-KLH Peptide Vaccine

Sponsor

Roswell Park Cancer Institute

Collaborators

[object Object]